Notice of AGM

Report this content

12 March 2020 11:00 GMT


Notice of Annual General Meeting


AstraZeneca PLC (the Company) announced today the publication of its Notice of Annual General Meeting 2020 and Shareholders' Circular (the Notice).


The Notice has been submitted to the National Storage Mechanism and will shortly be available for inspection at The Notice is also available on the Company's website at


The Company's Annual Report and Form 20-F Information 2019 was published on 3 March 2020.


The Notice is being despatched to shareholders today.


The meeting place for the Annual General Meeting (AGM) will be Leonardo Royal Hotel London Tower Bridge, 45 Prescot St, London, E1 8GP and the AGM will commence at 2.30 pm (BST) on 29 April 2020.


The Company continues to monitor the situation in relation to COVID-19 and will notify shareholders via our website, as soon as practicably possible if there are any changes to the AGM arrangements.  Shareholders are reminded of their right to appoint the Chairman of the AGM, or any other person, as their proxy to attend the meeting and vote on their behalf.



AstraZeneca (LSE/STO/NYSE: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas - Oncology, Cardiovascular, Renal and Metabolism, and Respiratory. Based in Cambridge, UK, AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. Please visit and follow the Company on Twitter @AstraZeneca.

Media Relations    
Gonzalo Viña   +44 203 749 5916
Rob Skelding Oncology +44 203 749 5821
Rebecca Einhorn Oncology +1 301 518 4122
Matt Kent BioPharmaceuticals +44 203 749 5906
Angela Fiorin BioPharmaceuticals +44 1223 344 690
Jennifer Hursit Other +44 203 749 5762
Christina Malmberg Hägerstrand Sweden +46 8 552 53 106
Michele Meixell US +1 302 885 2677
Investor Relations    
Thomas Kudsk Larsen   +44 203 749 5712
Henry Wheeler Oncology +44 203 749 5797
Christer Gruvris BioPharmaceuticals (Cardiovascular, Metabolism) +44 203 749 5711
Nick Stone BioPharmaceuticals (Renal) Environmental, Social and Governance +44 203 749 5716
Josie Afolabi BioPharmaceuticals (Respiratory)   +44 203 749 5631
Tom Waldron Other medicines +44 7385 033 717
Craig Marks Finance Fixed income +44 7881 615 764
Jennifer Kretzmann Corporate access Retail investors +44 203 749 5824
US toll-free   +1 866 381 72 77

Adrian Kemp
Company Secretary
AstraZeneca PLC


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact or visit



Documents & Links